Michael P. Flaherty, M.D., Ph.D.
Assistant Professor of Medicine, Physiology and Biophysics
Director, Adult Structural Interventions
Director, Research-Interventional Cardiology
Dr. Flaherty is an interventional cardiologist and clinician-scientist who received his training in percutaneous coronary, structural and peripheral interventions from The Johns Hopkins University, Baltimore, Maryland. He is an investigator on several adult stem cell trials that including the Cardiac Stem Cell Infusion in Patients With Ischemic CardiOmyopathy (SCIPIO) adult cardiac stem cell trial being conducted at UofL. He is also Principle Investigator of the PARTNER II - Placement of AoRTic TraNscathetERValves Trial (http://clinicaltrials.gov/ct2/show/NCT01314313) at the University of Louisville and Jewish Hosptial. His current basic science research is focused on molecular and cellular mechanisms of cardiac repair, namely, novel adult stem cell therapies aimed at reconstituting injured myocardium. Dr. Flaherty has developed and patented a method for improving heart function in mice following myocardial infarction that involves injecting bone marrow cells that have undergone Wnt11-induced cardiomyogenic differentiation into the infarcted murine myocardium. In addition, his current clinical research, in collaboration with the CORE 64 investigators from Johns Hopkins University, involves evaluating the accuracy of CT angiography vs. conventional coronary angiography in determining coronary lesion classification and severity.
Dr. Flaherty specializes in advanced percutaneous structural heart repair and is Director of the Adult Cardiac Structural Interventional Program at UofL. His other primary clinical focus is percutaneous coronary intervention with emphasis on high-risk coronary lesions.
Clinical Specialty:
Percutaneous coronary interventions; including high risk procedures requiring percutaneous mechanical support Percutaneous peripheral arterial interventions; Treatment of adult congenital heart disease: patent foramen ovale, atrial septal defects, pulmonic valvular stenosis and patent ductus arteriosus; Percutaneous treatment of valvular stenosis including aortic and mitral and pulmonic stenosis; Alcohol-induced myocardial septal ablation; Adult stem cell therapy for myocardial regeneration.
Clinical Research Interests:
Translational therapies for cardiovascular disease; Bone marrow and cardiac stem cell therapies for cardiac regeneration; Percutaneous aortic valve replacement; Phenotypic expression of hypertrophic cardiomyopathy; Cardiac marker expression in acute coronary syndromes; Mediators of myocardial Ischemic preconditioning.
Selected Publications:
- Flaherty MP, Guo Y, Tang SXL, Bolli R. Major impact of genetic and physiologic variables on ischemia/reperfusion injury in the murine heart. Basic Res Cardiol. (submitted)
- Flaherty MP, Dorfman T. Massive ST-segment Elevation Myocardial Infarction Owing To Anomalous Coronary Circulation. J Invasive Cardiol. (submitted)
- Flaherty MP, Johnston PV, and Rade JJ. Subacute Stent Thrombosis Owing to Complete Clopidogrel Resistance Successfully Managed With Prasugrel. J Invasive Cardiol. 2011 Jul;23(7):300-4.
- Flaherty MP, Dawn B and Solankhi NK. Iatrogenic Submedial Coronary Artery Intramural Hematoma Presenting Subacutely. J Invasive Cardiol. 2009 Jul;21(7):E128-31).
- Flaherty MP and Dawn B. Noncanonical Wnt11 Signaling and Cardiomygenic Differentiation. Trends In Cardiovasc Med. 2008 Oct;18(7):260-8.
- Dawn B, Abdel-Latif A, Sanganalmath SK, Flaherty MP, Zuba-Surma EK. Cardiac repair with adult bone marrow-derived cells: The clinical evidence. AntioxidRedox. 2009 Feb 9.
- Flaherty MP, Abdel-Latif A, Li Q, Hunt G, Ranjan S, Ou Q, Tang XL, Johnson RK, Bolli R, and Dawn B. Noncanonical Wnt11 Signaling is Sufficient to Induce Cardiomyogenic Differentiation in Unfractionated Bone Marrow Mononuclear Cells. Circulation. 2008; 117 (17): 2241-2252.
- Flaherty MP, Leesar MA, and Dawn B. Acute Myocardial Infarction in a 19-year-old Female Owing to the Hypercoagulable State of Pregnancy and the Puerperium. J Invasive Cardiol. 2008; 20(9):E262-4.
- Flaherty MP, Guo Y, Tiwari S, Rezazadeh A, Hunt G, Sanganalmath SK, Tang XL, Bolli R, Dawn B. The role of TNF-alpha receptors p55 and p75 in acute myocardial ischemia/reperfusion injury and late preconditioning. J Mol Cell Cardiol. 2008 Dec;45(6):735-41.
- Flaherty MP, Brown M, Grupp IL, Schultz JE, Murphree SS, Jones WK eNOS deficient mice develop progressive cardiac hypertrophy with altered cytokine and calcium handling protein expression. Cardiovasc Toxicol. 2007;7(3):165-77
- Dawn B, Xuan YT, Marian M, Flaherty MP, Murphree SS, Smith TL, Bolli R, Jones WK. Cardiac-specific abrogation of NF- kappa B activation in mice by transdominant expression of a mutant I kappa B alpha. J Mol Cell Cardiol. 2001 Jan;33(1):161-73.
- Jones WK, Flaherty MP, Tang XL, Takano H, Qiu Y, Banerjee S, Smith T, Bolli R. Ischemic preconditioning increases iNOS transcript levels in conscious rabbits via a nitric oxide-dependent mechanism. J Mol Cell Cardiol. 1999 Aug;31(8):1469-81.
For a complete list of publications, visit PubMed [Flaherty MP]
